Jefferies Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $39
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Jefferies analyst Maury Raycroft initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $39.
Jefferies analyst Maury Raycroft initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $39.